Ascendis Pharma (NasdaqGS:ASND) has drawn fresh attention after positive Week 52 Phase 2 New InsiGHTS data for TransCon hGH in Turner syndrome and long term ApproaCH trial results for TransCon CNP in achondroplasia.
On top of these trial updates, accelerated FDA approval for Yuviwel, the TransCon CNP treatment for achondroplasia, adds a new regulatory milestone that many investors are now weighing against Ascendis Pharma’s recent share performance.
See our latest analysis for Ascendis Pharma.
These clinical and regulatory milestones come against a backdrop of mixed recent trading, with a 7 day share price return of 5.67% and a 30 day share price decline of 4.74%. Meanwhile, the 1 year total shareholder return of 60.69% and 3 year total shareholder return of around 3x suggest longer term momentum has been stronger than the latest month implies.
If recent drug trial progress has you thinking more broadly about where healthcare and AI intersect, this is a good moment to look at 36 healthcare AI stocks
With Ascendis Pharma now carrying a market cap of about US$14.1b, a recent 1 year total return of 60.69% and an intrinsic discount estimate of around 72%, investors are asking whether there is still mispricing here or if the share price is already reflecting future growth.
Most Popular Narrative: 20.1% Undervalued
Ascendis Pharma's most followed narrative pegs fair value at about $286.75 per share versus the last close of $229.25, framing the current price as a discount that hinges on ambitious growth and profitability assumptions.
Regulatory progress and pipeline advancement, such as the priority review for TransCon CNP in achondroplasia and positive combination trial results, are paving the way for new blockbuster therapies and potential multi-billion EUR peak sales opportunities, enhancing future revenue growth and reducing revenue concentration risk.
Curious what kind of revenue climb and margin shift are built into that fair value, and how a future earnings profile reshapes the valuation multiple story.
Result: Fair Value of $286.75 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this upbeat fair value story still hinges on heavy reliance on Yorvipath and SKYTROFA, as well as on keeping R&D and global launch costs under control.
Find out about the key risks to this Ascendis Pharma narrative.
Another View: Market Ratios Flash a Different Signal
While the SWS model points to Ascendis Pharma trading at a 71.5% discount to estimated fair value, the current P/S of 17x tells a different story. That level is richer than the US Biotechs average of 11.1x, peers at 12.9x, and even the 13.1x fair ratio. This raises the question of how much optimism is already in the price.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
After reading this, do you feel the story is more exciting or more cautious? While the details are fresh, consider both perspectives for yourself with 4 key rewards and 1 important warning sign
Looking for more investment ideas?
While Ascendis Pharma might be front of mind right now, it can be useful to broaden your watchlist with a few targeted stock ideas so you are not relying on a single story.
- Target potential mispricing by reviewing companies highlighted in the 58 high quality undervalued stocks that combine discounted prices with stronger fundamentals.
- Strengthen your focus on resilience by checking companies in the 68 resilient stocks with low risk scores that screen well on stability and downside protection.
- Spot opportunities the crowd may be overlooking by scanning the screener containing 25 high quality undiscovered gems where quality metrics stand out despite limited market attention.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com